Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jakedog,
You get a big "AMEN" from me.
Regarding your BOD incestuous claim, I thought you might want to look at some clandestine video from one of the board's recent strategy meetings to deal with Ronin's unwanted involvement.
They were trying as hard as they could to come up with an alternative group of nominees for the board seats. They were also discussing a proposed letter to the governor to see if he would help them fend off Ronin's unwanted involvement in the Peregrine community. If you look closely you'll see see the proposed list of alternate nominees on the banner hanging in the background. I believe this is the list proposed by COB Carlton Johnson and I believe it helps to support your incestuous claim.
BOD nomination meeting
Also of interest is another clandestine video of a Peregrine community all hands meeting where SK is using his public speaking skills to to rally the troops so they will stay the course and not to give up and leave in the face of adversity. Eric Swartz seemed especially impressed by SK's speech.
Here is the video link:
Rallying the troops
Wernaaa,
I'm not saying that they didn't say in first half 2017. This is the only thing I could find in writing. You're welcome to find something else and post the source. No one is stopping you.
JEFF HUTCHINS (VP/PreClinical Res.) from 9-8-16 Qtr Conf Call.
It is our goal to develop, optimize and validate a functional screening assay capable of detecting PS positive exosomes in a blood sample and to initiate partnering discussions for commercialization of the program in 2017. We are on track to achieve this goal and we look forward to providing further updates.
CJ Post 272174
Masshysteria,
Thank you for your reply; it is much appreciated. It helps focus my thoughts on how this PR should be viewed for the short and long terms.
Glad you are still posting here.
Nuke
Masshysteria,
At the last quarterly conference call it was stated that some patients in sunrise are still receiving Bavi. We now know that a significant number of the PIII Bavi arm patients went on to Keytruda or Opdivo (based on the p values they are stating in this press release),
I'm wondering if there is the chance of a de-facto Bavi + (Keytruda or Opdivo) trial going on. Is there a possibility that the PIII Bavi arm patients who progressed to other immunotherapy treatments would also be allowed to continue to take Bavi at the same time as part of the compassionate use program?
Thanks in advance for your input
I have sort of an allegory for Peregrine for today's board. It's meant to be humorous. Please, no one take it personal.
Holy crap Batman,
Don't I feel like an idiot now. My real big bad bad. Never mind. Sorry about that folks and thanks jq1234 for setting me on the right path. I apologize to the board for making them read incorrect info.
jq1234,
The example of good DD is in the process where one presents their case and provides references to back up the statements. In response to your posting, getting back to the give and take of the DD process lets start with the clinicaltrials.gov website fort the Abraxane trial. The following are specifically listed as EXCLUSION criteria:
ex,
Thanks for the heads up on the math. However I don't think my mistake changes the facts; I just presented/described how to get them incorrectly.
When I stated the percentages for long term survival I said:
PPHMVERYLONG,
As a follow up to my post to you last night regarding the importance of performing due diligence research I'd like to provide the following as a brief example of where I think your due diligence is coming up short.
You stated:
Comparing Peregrines Pancreatic Trial to Celegene’s Pancreatic Trial
Trial Criteria Bavituximab (Peregrine) Abraxane (Celgene)
ECOG Status ≤ 2 ≤ 1
Stage 4 ≤ 2 (1)
Surgery as No Yes
Part of Study
PPHMVERYLONG,
You are obviously highly distressed with your long term losing investment in PPHM. You've stated you've been in it since 1999!!. WOW!! Watching a stock tank for so long; that kind of long term pain and stress will get the best of any seasoned investor let alone the average Joe who experiments with stock purchases. I don't know which one you are but I'm assuming that since you've held on for so long with a continuing and ever increasing loss I'll have to assume you are one of the average Joes, just like me. I try to empathize with peoples point of view and when appropriate also with their pain. You've obviously held on way beyond the point of where an experienced and savvy trader or investor (not us obviously don't you think) ever would. I've always told myself when I've found myself in similar situations that its due to my lack of experience or my inability to perform rudimentary personal due diligence.
Please don't be insulted (I've no intention here of insulting anyone) but here are some links that I think will help you form a better plan for selecting stocks to invest in; they have helped me. Also, I've provided some links that I believe every investor should read to ensure they have a plan in place to know when to sell a losing position so that the novice and experienced alike can preserve their capital and move on to a hopefully more fruitful investment.
Remember, its not reasonable to expect every investment to be profitable and its important to know when cut and run and move on. You know PPHMVERYLONG even the best investors lose money in the stock market so you are not alone and you really shouldn't let it get to you so much. Stress really is a killer you know.
From what I've read what separates the winners from the losers is knowing how to sell a losing position, especially one in which the person is only holding on hoping against hope that it will ever get back to or even near break even.
Links for selecting stocks for investing:
Definition of Due Diligence; I always start with this as a reminder of what I should be doing before spending my hard earned money on a stock
10 Easy Steps for Due Diligence
I find this site very helpful when I have to go back to square one after taking a knee in the groin due to a bad investment. It gets me re-centered
This is the checklist I use when I get serious on a stock. I strongly recommend this checklist when you think you've found your next stock. I don't think anyone should invest until they've performed the items in this checklist.
I use the strategies outlined in this document to gauge a company's plans against to see if they are going to be a strong candidate to succeed. I highly suggest you incorporate this information into your due diligence strategies.
These links have been invaluable to me to prevent me from holding on to losing positions especially when I've lost faith but am thinking about hanging on just hoping against all hope that the investment will turn around and I'll get something back. Again, I highly recommend having an exit strategy always at hand; for both positive gains and negative losses. I can't stress how much this has helped me and its my wish that you get something out of developing a strategy that these sites have helped me:
The Art of Selling a Losing Position
Stop Loss Orders and How to Use Them; I love this info and highly recommend it. It has saved me lots of grief. However, as a long investor in PPHM my personal opinion is that I wouldn't use it for Peregrine but I'm willing to take more risk. I might wish I would have used it someday if I end up in your position with PPHM (in a losing stock for 17 years and not able to get out. Please believe me when I say that this isn't a slur against you, just a recognition that I hope not to end up in your shoes with PPHM) but for now I'm willing to take the risk and accept the consequences without blaming anyone but myself.
This keeps me from going to far in a single stock and shows me how to control my money during the investment
AAII Recommendations of falling stock
I sincerely hope these links help you in your next investment so that you can be profitable and not caught in an investment where you find it impossible to extricate yourself from; I hate to see people lose their honest hard earned money. I would enjoy hearing some feedback if you find these sites helpful as I will know whether or not I should recommend them to others in similar situations. I know they've worked for me but not everyone gets the same benefits from the same information as I'm sure we are all well aware. Good luck PPHMVERYLONG and maybe some day we'll meet at the ASM and we can exchange notes on our PPHM investment experience.
For some of us this petition to the SEC from NASDAQ can't be implemented soon enough.
Nasdaq Asks SEC for Short Position Disclosure
I would love to see the SEC issue regulations to require short position reporting as requested in the petition and then maybe some of the blatant market manipulations of PPHM stock will be much harder to pull off.
Some of the points made in the NASDAQ petition:
north,
Here is the link for the slide presentation for the 2014 ASM. I believe these are the ones you're looking for. Again, thanks to CJGaddy for having this in the intro section. Too bad the audio link doesn't work.
2014 ASM slide info
ex,
Although the trial was stated to be HER2 negative it did not exclude triple negative patients. In fact about half (~4) of the patients were triple negative. I know, I know... this number is small but it is an encouraging data point. This information was extracted from this Peregrine news release
Jake,
Yeah, I've had my doubts every once in awhile. But, I'm still here. Sometimes I wonder if I'm related to Mr. Douglas and Peregrine is Mr Haney. This is just for humor guys, its not meant to be a bash against Peregrine. Its just a statement about how I've questioned my sanity at times over the years.
Mr Douglas and Mr Haney
jakedog,
Thanks for this link and info. Great stuff to know especially for us Peregrine investors in our current state of affairs. These are the key excerpts for me so far:
sulaco,
I agree with everything you said. However my assessment of what impact these ISTs are having with BPs is probably different than yours based on the actions that management has taken over the last half of this year. Please see my response I just made to Couch on how I'm seeing things. Believe me, I'll be the first one who will be jumping for joy if the deal comes in much earlier than I expect.
Couch,
I'm guessing that its going to take a combination of good Sunrise interim data and good ORR data from 2 of the 3 new trials. One of the major reasons I supported (probably the major reason) the increased share authorization was because I was hearing from management that we needed more "relevant" or "more firm" data than we currently have. And, as far as the great breast cancer IST data we already have someone (some BP(s) who count(s)) must want more data than that obtained from 13 patients.
They should get breast cancer started by end of this month and the new bavi + AZN IO by February (of course that's a guess). We don't need big enrollment numbers but, how many I don't know. I would guess that it would be anywhere between 40 and 80 per trial. I would think that getting 40 patients enrolled in Bavi + durvalumab for NSCLC should be a slam dunk and should be accomplished well within 6 months and probably a lot sooner with AZN helping. I'm sure they'll be supporting this trial using their influence and contacts to ensure it is expedited along with providing free durvalumab. As AZN is also supporting the multi tumor types with free durvalumab I assume this extra help will be extended for that trial too.
I don't know how long it would take to get 40 breast cancer patients but I know Moffit here in FL is big in this area and is also involved with Bavi trials. I assume this goes for other centers used in the Sunrise trial as well. I would think that 40 patients for breast cancer should also be able to be enrolled within 6 months because we have established lots of working relationships with large cancer centers via Sunrise. This first phase 3 must have opened lots of doors and created lots of working relationships. This all saves time for quick follow on studies as long as we have the money to keep the process moving along.
I'm guessing that there is a small probability that we get the big deal between now and April but I believe the real high probabilities will be once we have Sunrise 2nd interim which management describes as mid-year. These are going to be open label trials if I remember correctly so new trial ORR data will/should be available day by day. So I believe from June on the probability of the deal closing out of the blue gets much greater.
I don't think there is anyway in hell that there won't be a BP deal with good interim Sunrise data, along with confirmation of superior response rates with anti PD-L1 drug in multiple applications and confirmation of the great breast cancer response rates we've already obtained and all this based on OUTSTANDING pre-clinical translational data.
It looks like management has planned a full court press for this year. We'll just keep delivering great pre-clinical (from MSK too) and multiple clinical data until someone hands us that big check we've been waiting for.
BCS,
That's just not true. You've had many chances to look like a genius.
Wook,
I believe translational data has been out there for more than enough time to close the deal if it was going to be the driver. I also believe translational data has been the driver to get MSK and AZN to work with us which is great. But when it comes to icing the big deal I believe what I stated in my post; that management believes its going to take human trial validation up to at least response data in more than just a Bavi + chemo trial to get the big deal closed.
Otherwise why did management jump through so many hoops (asking for such a large share increase to ensure significantly more monies than needed to open Avid II and bring in Sunrise data, the hurry up and get the breast cancer trial and Bavi + AZN IO for NSCLC and multiple tumor types trials going ASAP) in such a short period? I still believe that management believes that the ORR data from these new trials is required to close the big deal. I also believe they base this on the feedback they are getting in their "partnering discussions" or they wouldn't spend the money to do this.
Its evident enough to me after being in this stock over 10 years now and looking at the Biotech world for the amount of time that I have, that human clinical trial data "talks" and pre-clinical data walks. Unless of course someone wants to sell on the cheap.
And by the way I've already bought mine. I'm still digging to find the large vein, screw the nuggets.
JamesGMS,
If you don't mind I'd like to get in on this conversation and try to share some of my thoughts as this subject because I believe it is the foundation for investment decisions for most of us. You stated:
What's your point? It's certainly a good thing for ~2% of the NSCLC population but what about the rest of the patients. How many 10's of millions (if not hundreds of millions) of dollars went into this drug for generating a response in only about 2% of the entire NSCLC group. OBVIOUSLY a long way still to go. How do you think the Bavi+Chemo+ant-PD-L1 trial (which is taking all comers; including squamous) will end up doing? The only real ticking clock here is the one the NSCLC patients are hearing without having access to much better treatments than just Alecensa.
FDA Approval Letter for Alecensa
ex,
I'm going to agree with you on that because I have a memory of one of the PPHM people (I think it was Shan but not sure) who made a comment, in either the annual or a quarterly, that stuck in my head;
he said that the first interim would occur when the number of events happened and after completion of enrollment. He made the comment kind of fast and fading in volume in response to a question but the way he said it made it stick in my head. I was going to research this a couple of times but blew it off.
I see it as full enough:
CP,
Thanks for the response and the effort it took. I found it very interesting and informative.
Are you sure you don't have a staff working with you (and I don't mean the dog or the concierge either) to be able to produce so much info in so short a time? Just to be sure you understand, I'm only kidding. It takes me an hour to write a single paragraph sometimes.
North,
I wasn't as much interested in Ebola specifically but in how Peregrine thinks it has a better understanding of its anti-viral MOA in general. I took SK's response about an ebola specific question as being directed towards Bavi's anti-viral action in general based on his choice of words.
He chose to respond with "...viral moves so fast..." not that "ebola virus moves so fast". I believe the statement that "...viral moves so fast..." is applicable to viral infections in general. Of course this is all conjecture on my part.
I'm very interested in the viral program and I'd like to hear more about progress on that front. If indeed they believe they have a new understanding of Bavi anti-viral MOA I'd certainly like to hear what it is. This would allow us a chance to assess the potential of the Bavi anti-viral platform, and it gives us something else to talk about while we wait for the myriad other events to occur.
north,
I know this is not directly related to what you were discussing in your post but it does deal with Bavi and its efficacy regarding viruses. When I was recently poking around for information about what Dr. Garnick said about our timeline for Bavi approval process after completion of Sunrise, I saw this question and answer exchange with Steve King that occurred during the 2014 annual shareholders meeting:
ex,
Thanks for responding. I'm glad we are on the same page. It bothers me when I think I know something to be correct and then have someone with your experience say something to the contrary.
With respect, I sorta kinda do and sorta kinda don't agree with your statement:
ex,
To be clear when you said:
Thanks BioBS. It makes me feel better knowing that I'm not out to lunch or at least you are in agreement with a key piece of information that I've been using.
Wook,
I also considered SK was making assumptions when he said it. I thought the major input to the assumptions back then would be the information they had from PII and expected enrollment curves for PIII. The PII data is a fixed item and the only major variable that I can see is how actual enrollments coincided with the expectations they had back then. Without having to go back and pull up the actual data I believe that site ramp up was very significant by the first 7 months and I can't see how they could have expected any better. The actual unknown is how well enrollment actually occurred over time. SK has always said they have been on track so in essence that is the major factor for me. I know there are going to be a lot of people here who wouldn't consider SK's comments on enrollment as reliable but I'm not one of those.
Thanks CP.
BioBS2012,
You stated:
tradero,
I'll have to wait for Friday's happy hour to send you my email. Unlike MD I have no desire for the world to know who I am.
Thanks for letting me know tradero.
Well, I've given up trying to find the 2014 ASM transcript so I'll get back to what I was originally going to discuss. Steve King said to a shareholder(s) during the 2014 ASM (after the official program presentation was over) that he expected the 2nd look-in to occur by the end of 2015. Now, more recently, SK is saying he doesn't expect 2nd lookin until mid 2016. All along SK has been saying enrollment is on track, therefore assuming SK hasn't been BS'ing us on the enrollment, the movement of the expected 2nd look-in from expected end of 2015 (back in October of 2014) to mid 2016 (stated in this years ASM) should mean the trial is going much better than expected. I believe this assessment will be greatly bolstered if we indeed get an enrollment complete before the end of this year; which provides validation of SK being honest on how enrollment has been proceeding.
That's the same result I've been having. Usually someone posts a transcript to the board. The 2014 ASM transcript seems to be MIA.
Thanks for your help gp100
goodplenty100,
I appreciate the effort but the link was to the Nike ASM.
Thanks.
I've been poking around the intro section looking for the transcript info where I remember Dr. Garnick laying out in long boring detail how he expected the Sunrise trial and BLA submission process to proceed. In the process of doing this I came across some interesting info that I think is relevant to discuss at this time. But before I get to that I'd like to ask anyone if they have a transcript of the 2014 annual shareholders meeting. The link in the intro box that CJ has leads to a webcast archive that is no longer available. I would greatly appreciate it if anyone who has search capability for old posts could track down a text transcript of that meeting,
Now regarding the interesting things that I've seen during this search.
First this is from an intro section link of the 2014 ASM that consolidates poster reports from people who attended the 2014 ASM:
Wook,
I reviewed this again after our last discussion on this topic and I came to the conclusion that the MOA is two fold with an FC gamma binding and by blocking the binding of phosphatidylserine-positive microvesicles to phosphatidylserine receptors on TAMs. Of course this is hypothesized MOA based on this study done by UTSW . This the discussion from that paper: